Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21 Leukemia 9 Gastrointestinal Stromal Tumors 4 Philadelphia Chromosome 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid 3 Bone Marrow Diseases 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Myeloproliferative Disorders 2 Hematologic Neoplasms 2 Bronchiolitis Obliterans Syndrome 2 Sarcoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Hematologic Diseases 1

Interventions

Doxorubicin 25 Ifosfamide 22 Radiotherapy 17 Etoposide 11 Vincristine 10 Cyclophosphamide 10 Filgrastim 8 Dactinomycin 8 Trabectedin 7 Chemotherapy, Adjuvant 5 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Neoadjuvant Therapy 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Dacarbazine 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Epirubicin 2 Docetaxel 2 Dexrazoxane 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × nilotinib × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡